The company "Syneuro" develops international cooperation within the framework of project on the design of novel medicines.


Professor V. I. Tsetlin (head of the Department of molecular bases of neurosignaling of Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of Russian Academy of Sciences and scientific supervisor of the company) has initiated the visit of Professor Wolfgang Kummer (the head of the laboratory of the Institute of Anatomy and Cell Biology, Yustus Liebig University, Giessen, Germany) to Russia which was supported by Alexander von Humboldt Foundation and the German House of Science and Innovation. Prof. W. Kummer is one of the world leading experts in study of molecular mechanisms responsible for the physiologically important processes in the lungs and respiratory tract. In addition to his many responsibilities in international scientific organizations and societies, he is also a working expert of SKOLKOVO. In the frame of this visit Prof. W. Kummer gave on May 22, 2012 in Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry the public Humboldtian lecture "Before neurons were born: a non-neuronal acetylcholine".

After his lecture Prof. W. Kummer visited the laboratory rooms of the company "Syneuro" and discussed with the company team the cooperation perspectives in the framework of the project for the studies of the peptides from the venom of the snake Azemiops feae. This venom from the rare reptile, caught in Northern Vietnam with the assistance of the Vietnamese scientists, is poorly characterized and that is why even its first studies (performed by employees of company "Syneuro", Shemyakin-Ovchinnikov Institute and several foreign laboratories) discovered a new polypeptide targeting the muscle nicotinic receptors which is the first member of a new toxin group (Utkin et al, J. Biol. Chem., 2012). Taking into account the fact that these receptors are involved in a number of normal and pathological processes in the lungs and epithelium, an agreement was reached that Prof. W. Kummer will take part in studies of above-mentioned and the other purified peptides testing their activities on different classes of ligand-gated ion channels in the lungs and endothelial tissues. That work will be fulfilled at Institute of Anatomy and Cell Biology in Giessen.


Current company activities are supported by grants:

1. Foundation of assistance to development of small enterprises in scientific and technical sphere. State contract # 9037р/14817. "Conotoxin analogs as a basis for design of peptide analgesics of new generation ".

2. The Ministry of education and science. State contract # 16.512.11.2207. "Synthesis and pharmacological characterization of a new peptide blocker of nicotinic cholinoreceptors perspective for design of a new type myorelaxants".


Publications:


1. Yu. N. Utkin, Ch. Weise, A. Hoang Ngoc, I. E. Kasheverov, V. G. Starkov, V. I. Tsetlin. New peptide from the Fea's viper Azemiops feae venom interacts with nicotinic acetylcholine receptors. Dokl. Biochem. Biophys. (2012), 442, 33-35.


2. Yu. N. Utkin, Ch. Weise, I. E. Kasheverov, T. V. Andreeva, E. V. Kyukova, M. N. Zhmak, V. G. Starkov, A. Hoang Ngoc, D. Bertrand, J. Ramerstorfer, W. Sieghart, A. J. Thompson, S. C. R. Lummis, V. I. Tsetlin. Azemiopsin from Azemiops feae viper venom, a new polypeptide ligand of nicotinic acetylcholine receptor. J. Biol. Chem. (2012), in press.


Patents:

1. Direct thrombin inhibitor, possessing antiproliferative action. The patent for the invention № 2369615 (RU). Effective date for property rights: 24.08.2007. License contract (exclusive license) № RD0081754 for a term of patent validity. Licensee: LLC "Syneuro" (RU).

2. Peptide azemiopsin selectively interacting with muscle type nicotinic cholinoreceptors and suitable for use as a myorelaxant in medicine and cosmetology. Patent application for invention № 2011143065 from 26.10.2011.